.. Amira to provide AM152 preclinical data in fibrotic disease at ATS Annual Meeting Amira Pharmaceuticals, Inc. Announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.m. MDT. The LPA1 receptor is part of the lysophosphatidic acid signaling pathway. Our preclinical data demonstrate that AM152 reduces pro-fibrotic activity by fibroblasts in vitro and cells fibrosis in numerous in vivo models, said Gretchen Bain, Ph.D., Executive Director of Biology.2009;301:1460-1467.
Scientific results of INVO process of treatment of infertility announced INVO Bioscience announced that CECOLFES retrieved per affected person. Elkin Lucena, who owns and runs the CECOLFES fertility center. CECOLFES has also opened several INVO treatment centers within the region. Related StoriesNew paper device could and inexpensively assess hepatitis B rapidly, male infertilityARC Telehealth Program allows fertility sufferers connect with doctors through cellular devicesCCRM Network companions with ACRM to supply outstanding patient treatment in the southeastern U.S. Ranoux using our prototype device demonstrated pregnancy rates in the range of traditional IVF.. YOUR GOVERNMENT U.S. Federal government Subpoenaed Amazon.com to acquire Book Purchasing Information of Customers Newly unsealed court public records have got revealed that the U.S.